QIAGEN (NYSE: QGEN) trims 2026 growth targets as Q1 EPS and cash flow decline
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
QIAGEN N.V. reported Q1 2026 results showing modest sales growth but weaker earnings and a lower outlook. Net sales were $492 million, up 2% reported but down 1% at constant exchange rates. GAAP net income fell to $68 million, with diluted EPS declining to $0.33 from $0.41.
Adjusted diluted EPS was $0.54, slightly below $0.55 a year earlier, with an adjusted operating margin of 27.4% versus 29.8%. Growth pillars such as Sample technologies, QIAcuity and QIAGEN Digital Insights expanded, but QuantiFERON sales declined 5% at constant exchange rates due to sharply lower immigration testing demand.
Free cash flow dropped to $53.7 million from $95.8 million as operating cash flow declined and capital investments increased. QIAGEN cut its full-year 2026 guidance to 1–2% net sales growth at constant exchange rates and at least $2.43 adjusted diluted EPS, down from prior targets of at least 5% CER sales growth and at least $2.50 EPS.
Positive
- None.
Negative
- 2026 outlook cut: Net sales guidance reduced from at least 5% to about 1–2% constant-currency growth, and adjusted EPS guidance lowered from at least $2.50 to at least $2.43.
- Earnings and cash flow down: Q1 2026 GAAP diluted EPS declined 20% to $0.33, adjusted EPS dipped to $0.54, and free cash flow fell 44% to $53.7 million.
Insights
Guidance cut and softer earnings offset QIAGEN’s Q1 growth pillars.
QIAGEN delivered Q1 2026 net sales of $492.3M, up 2% reported but down 1% at constant exchange rates. GAAP net income fell to $68.0M and diluted EPS to $0.33, while adjusted EPS slipped to $0.54.
Profitability remained relatively strong with a 27.4% adjusted operating margin, but this was below the prior-year 29.8% as integration of Parse Biosciences, tariffs and currency headwinds weighed on results. Free cash flow declined sharply to $53.7M from $95.8M, reflecting lower operating cash flow and higher capital expenditures.
The most material development is the reduced 2026 outlook: net sales growth of about 1–2% CER and adjusted EPS of at least $2.43, down from at least 5% CER growth and at least $2.50. Management cites weaker QuantiFERON immigration testing, cautious U.S. Life Sciences demand and geopolitical uncertainty as key headwinds.
Key Figures
Q1 2026 net sales: $492.3M
Q1 2026 GAAP diluted EPS: $0.33
Q1 2026 adjusted diluted EPS: $0.54
+5 more
8 metrics
Q1 2026 net sales
$492.3M
Up 2% reported, down 1% at constant exchange rates vs Q1 2025
Q1 2026 GAAP diluted EPS
$0.33
Down from $0.41 in Q1 2025, a 20% decline
Q1 2026 adjusted diluted EPS
$0.54
Slightly below $0.55 in Q1 2025; in line with $0.54 CER outlook
Adjusted operating margin
27.4%
Q1 2026 margin vs 29.8% in Q1 2025
Free cash flow Q1 2026
$53.7M
Down from $95.8M in Q1 2025 due to lower operating cash flow and higher capex
QuantiFERON Q1 2026 sales
$113M
Down 5% at constant exchange rates vs Q1 2025
2026 net sales guidance
1–2% CER growth
Reduced from at least 5% constant-currency growth previously
2026 adjusted EPS guidance
At least $2.43 CER
Lowered from at least $2.50 CER
Key Terms
constant exchange rates (CER), adjusted diluted EPS, free cash flow, synthetic share repurchase, +1 more
5 terms
constant exchange rates (CER) financial
"Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER)"
A way of reporting financial results that removes the effect of currency swings by redoing past figures using the same exchange rates as the current period. For investors, it shows the company’s underlying performance — like comparing the sizes of apples using the same ruler — so growth or decline reflects real business activity rather than changes in foreign-currency values.
adjusted diluted EPS financial
"Diluted EPS of $0.33; adjusted diluted EPS of $0.54, also $0.54 CER in line with outlook"
Adjusted diluted EPS is a company’s profit per share after adding back or removing one-time items (like restructuring costs or gains) and dividing by the number of shares including potential shares from options and convertible securities. Investors use it as a cleaner view of ongoing earnings—like looking at a car’s regular fuel efficiency rather than a trip boosted by downhill coasting—to judge underlying performance and compare companies without temporary distortions.
free cash flow financial
"We use a measure of free cash flow to estimate the cash flow remaining after purchases of property, plant and equipment"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
leverage ratio financial
"The leverage ratio (net debt to adjusted EBITDA) increased to 1.3x at the end Q1 2026 from 0.7x"
Leverage ratio measures how much a company relies on borrowed money compared with its own funds or assets, typically expressed as debt relative to equity or total assets. Like a homeowner with a mortgage, higher leverage can amplify returns when business is strong but also raises the chance of big losses or default if revenue falls, so investors use it to judge financial risk and resilience.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________
FORM 6-K
__________________________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the quarterly period ended March 31, 2026
Commission File Number 001-38332
__________________________________
QIAGEN N.V.
(Translation of registrant’s name into English)
__________________________________
Hulsterweg 82
5912 PL Venlo
The Netherlands
(Address of principal executive office)
__________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ý Form 40-F o
1
Table of Contents
QIAGEN N.V.
Form 6-K
TABLE OF CONTENTS
| Item | Page | ||||
| Other Information | 3 | ||||
| Signatures | 4 | ||||
| Exhibit Index | 5 | ||||
2
Table of Contents
OTHER INFORMATION
On May 6, 2026, QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) issued a press release announcing its unaudited financial results for the first quarter ended March 31, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
QIAGEN has regularly reported adjusted results, which are considered non-GAAP financial measures, to give additional insight into our financial performance as a supplement to understand, manage, and evaluate our business results and make operating decisions. We also use the adjusted results when comparing to our historical operating results, which have consistently been presented on an adjusted basis.
Adjusted results should be considered in addition to the reported results prepared in accordance with U.S. generally accepted accounting principles, but should not be considered as a substitute. Reconciliations of reported results to adjusted results are included in the tables accompanying the press release. We believe certain items should be excluded from adjusted results when they are outside of our ongoing core operations, vary significantly from period to period, or affect the comparability of results with the Company’s competitors and our own prior periods.
The non-GAAP financial measures used in this press release are non-GAAP gross profit, operating income, pre-tax income, net income, tax rate and diluted earnings per share. These adjusted results exclude costs related to business integration, acquisition and restructuring related items, long-lived asset impairments, amortization of acquired intangible assets, non-cash interest expense charges as well as other special income and expense items. Management views these costs as not indicative of the profitability or cash flows of our ongoing or future operations and therefore considers the adjusted results as a supplement, and to be viewed in conjunction with, the reported GAAP results.
We use a measure of free cash flow to estimate the cash flow remaining after purchases of property, plant and equipment as required to maintain or expand our business. This measure provides us with supplemental information to assess our liquidity needs. We calculate free cash flow as net cash from operating activities less purchases of property, plant and equipment.
We also consider results on a constant currency basis. Our functional currency is the U.S. dollar and our subsidiaries’ functional currencies are the local currency of the respective countries in which they are headquartered. A significant portion of our revenues and expenses is denominated in euros and currencies other than the United States dollar. Management believes that analysis of constant currency period-over-period changes is useful because changes in exchange rates can affect the growth rate of net sales and expenses, potentially to a significant degree. Constant currency figures are calculated by translating the local currency actual results in the current period using the average exchange rates from the previous year’s respective period instead of the current period.
We use non-GAAP and constant currency financial measures internally in our planning, forecasting and reporting, as well as to measure and compensate our employees. We do not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.
3
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| QIAGEN N.V. | ||||||||
| By: | /s/ Roland Sackers | |||||||
| Roland Sackers | ||||||||
| Chief Financial Officer | ||||||||
Date: May 7, 2026
4
Table of Contents
EXHIBIT INDEX
Exhibit No. | Exhibit | |||||||
99.1 | Press Release dated May 6, 2026 | |||||||
5
Exhibit 99.1
| Media Release |  | |||||||
QIAGEN reports full results for Q1 2026
•Q1 2026 results in line with pre-announcement:
◦Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth
◦Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand
◦Diluted EPS of $0.33; adjusted diluted EPS of $0.54, also $0.54 CER in line with outlook
◦Adjusted operating income margin at 27.4%, as ongoing high level of profitability absorbs Parse investments and headwinds from tariffs and currency movements
•Updated full-year 2026 outlook reconfirmed: Net sales growth of about 1-2% CER and adj. diluted EPS of at least $2.43 CER
Venlo, the Netherlands, May 6, 2026 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary announcement, showing QIAGEN continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.
As announced April 27, net sales for Q1 2026 rose 2% on a reported basis to $492 million, while sales at constant exchange rates (CER) were down 1%, compared with the outlook for at least 1% CER growth. Adjusted diluted EPS CER of $0.54 CER was in line with the outlook for at least $0.54 CER.
QIAGEN’s growth pillars together grew 4% CER compared to Q1 2025. Sample technologies delivered 9% CER growth compared with Q1 2025, and 3% CER growth excluding the Parse acquisition, supported by demand for automated consumables and instrument placements. QIAcuity digital PCR delivered double-digit CER sales growth on higher consumables and instrument sales over the year-ago period. QIAGEN Digital Insights (QDI) posted solid single-digit gains led by clinical bioinformatics. QIAstat-Dx sales declined 1% CER as expected against tough prior-year results. QIAstat-Dx consumables sales rose despite a weaker respiratory season on double-digit CER growth from recently launched Gastrointestinal and Meningitis panels in the U.S., while QIAstat-Dx instrument placements continued at a good level.
QuantiFERON sales declined 5% CER from Q1 2025, mainly due to a significant decline in immigration testing demand in the United States and the Middle East. Trends remained solid in other patient testing groups. QIAGEN now expects QuantiFERON full-year 2026 sales to be unchanged at CER compared with 2025 sales of $503 million.
QIAGEN updated on April 27 its full-year 2026 outlook for net sales to grow about 1-2% CER (previously at least 5% CER growth), driven by headwinds from the reduced QuantiFERON immigration testing demand, sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least $2.43 CER (previously at least $2.50 CER).
1
“QIAGEN made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologies, QIAcuity and QIAGEN Digital Insights,” said Thierry Bernard, Chief Executive Office of QIAGEN. “QuantiFERON was affected by significant decline in immigration testing demand, but we view this as a rebasing of demand within this testing group during 2026 and not a change in the overall long-term opportunity for latent TB testing. We are focused on executing against our updated 2026 targets and positioning QIAGEN for faster growth in the second half of 2026."
“Our profitability for the first quarter reflected disciplined execution in a challenging environment, as we managed the impact of supporting portfolio investments, as well as headwinds from tariffs, currency movements and measures to ensure reliable product supply,” said Roland Sackers, Chief Financial Officer of QIAGEN. “We are focused on delivering solid profitable growth through efficiency gains combined with disciplined capital allocation and targeted investments that strengthen QIAGEN's long-term growth potential and create value for shareholders.”
Key figures
| In $ millions (Except EPS and diluted shares) | Q1 | |||||||||||||||||||
| 2026 | 2025 | Change | ||||||||||||||||||
| Net sales | 492 | 483 | +2 | % | ||||||||||||||||
| Net sales - CER | 477 | -1 | % | |||||||||||||||||
| Operating income | 84 | 115 | -27 | % | ||||||||||||||||
| Net income | 68 | 91 | -25 | % | ||||||||||||||||
| Diluted EPS | $0.33 | $0.41 | -20 | % | ||||||||||||||||
| Diluted shares (in millions) | 209 | 220 | ||||||||||||||||||
| Adjusted operating income | 135 | 144 | -7 | % | ||||||||||||||||
| Adjusted net income | 113 | 121 | -7 | % | ||||||||||||||||
| Adjusted diluted EPS | $0.54 | $0.55 | -2 | % | ||||||||||||||||
| Adjusted diluted EPS - CER | $0.54 | -2 | % | |||||||||||||||||
Please refer to accompanying tables in this release for full income statement information and a reconciliation of reported to adjusted figures.
Tables may have rounding differences. Percentage changes are to prior-year periods.
•Sales: Net sales were $492 million in Q1 2026, rising 2% at actual rates and declining 1% CER compared with Q1 2025. Results reflected solid growth in several areas of the portfolio, offset by significantly lower QuantiFERON immigration testing demand and cautious spending among U.S. Life Sciences customers. Sample technologies rose 9% CER, including contributions from the Parse acquisition completed in late 2025, and grew 3% CER excluding Parse. Genomics / NGS sales rose 4% CER, supported by growth in the QIAGEN Digital Insights bioinformatics business. Diagnostic solutions declined 4% CER, mainly due to the 5% CER decline in QuantiFERON sales and the discontinuation of NeuMoDx. Overall, consumables and related revenues declined 1% CER, while instrument sales were down 6% CER, reflecting the cautious capital spending environment among U.S. Life Sciences customers.
•Operating income: Operating income was $84 million compared to $115 million in Q1 2025. Adjusted operating income, which excludes various charges and other items in both periods, declined 7% to $135 million. The adjusted operating income margin was 27.4% of sales compared with 29.8% in Q1 2025, reflecting investments in Parse following the November 2025 acquisition and headwinds from tariffs and adverse currency movements that were partially offset by efficiency gains and cost discipline. The adjusted gross margin was 66.1% compared with 67.4% in the prior-year period, primarily due to tariffs. Sales and marketing expenses increased to 23.3% of sales from 22.0% in Q1 2025, in part due to Parse investments, while general and administrative expenses declined to 5.6% from 6.5% in the year-ago period.
2
•Earnings per share (EPS): Diluted EPS was $0.33 compared to $0.41 in Q1 2025. Adjusted diluted EPS was $0.54, or $0.54 CER, in line with the outlook for at least $0.54 CER, compared to $0.55 in Q1 2025. The adjusted tax rate was 18% in Q1 2026, while the diluted share count was 208.9 million, both in line with QIAGEN's planning assumptions.
Sales by product groups
In $ millions | Q1 | |||||||||||||||||||||||||
2026 sales | 2025 sales | Change | CER change | |||||||||||||||||||||||
| Sample technologies | 170 | 150 | +13 | % | +9 | % | ||||||||||||||||||||
| Diagnostic solutions | 185 | 187 | -1 | % | -4 | % | ||||||||||||||||||||
| Of which QuantiFERON | 113 | 116 | -3 | % | -5 | % | ||||||||||||||||||||
| Of which QIAstat-Dx | 36 | 34 | +4 | % | -1 | % | ||||||||||||||||||||
| Of which NeuMoDx | — | 6 | -100 | % | -100 | % | ||||||||||||||||||||
| Of which Other | 36 | 31 | +19 | % | +15 | % | ||||||||||||||||||||
| PCR/Nucleic acid amplification | 69 | 76 | -9 | % | -13 | % | ||||||||||||||||||||
| Genomics/NGS | 57 | 53 | +6 | % | +4 | % | ||||||||||||||||||||
| Other | 12 | 18 | -31 | % | -31 | % | ||||||||||||||||||||
| Total net sales | 492 | 483 | +2 | % | -1 | % | ||||||||||||||||||||
Tables may have rounding differences. Percentage changes are to prior-year periods.
•Sample technologies: Sales rose 9% CER in Q1 2026 to $170 million, driven by double-digit CER growth in automated consumables compared with Q1 2025, and were up 3% CER excluding contributions from the Parse acquisition. Growth in automated consumables kits more than offset a single-digit CER decline in manual kit sales. Parse performed well in the quarter and is expected to deliver above the 2026 sales target of $40 million. Instrument placements also showed good momentum, as QIAGEN advances the 2026 rollout of QIAsymphony Connect, QIAsprint Connect and QIAmini.
•Diagnostic solutions: Sales declined 4% CER in Q1 2026 to $185 million. QIAstat-Dx declined 1% CER reflecting the reduced demand for respiratory panels. QuantiFERON latent TB sales declined 5% CER, due to sharp drop in immigration testing demand in the U.S. and the Middle East, while trends remained solid in other patient testing groups.
•PCR / Nucleic acid amplification: Sales were down 13% CER in Q1 2026 to $69 million compared with the prior-year period. QIAcuity sales grew at a solid double-digit CER rate, supported by growth in both consumables and instruments. This was more than offset by declines in OEM sales due to customer timing and also lower sales contributions from PCR consumables.
•Genomics / Next-generation sequencing (NGS): Sales rose 4% CER to $57 million compared to Q1 2025. QIAGEN Digital Insights (QDI) posted solid single-digit gains led by clinical bioinformatics. Consumables sales of universal NGS panels were higher, while instrument sales declined at a double-digit CER rate.
3
Key cash flow data
| In $ millions | Q1 | |||||||||||||||||||
| 2026 | 2025 | Change | ||||||||||||||||||
| Net cash provided by operating activities | 101 | 140 | -28 | % | ||||||||||||||||
| Purchases of property, plant and equipment | (47) | (44) | +7 | % | ||||||||||||||||
| Free cash flow | 54 | 96 | -44 | % | ||||||||||||||||
| Net cash provided by investing activities | 211 | 120 | NM | |||||||||||||||||
| Net cash used in financing activities | (504) | (287) | NM | |||||||||||||||||
Tables may have rounding differences. Percentage changes are to prior-year periods.
•Net cash from operating activities was $101 million in Q1 2026 compared with $140 million in Q1 2025, with results in the 2026 period including about $7.8 million in cash payments for the ongoing efficiency and restructuring programs, as well as an increase in inventory levels in light of geopolitical conditions and in preparation for new product launches. Free cash flow was $54 million in 2026 compared to $96 million in 2025, reflecting a higher level of investments during Q1 2026 for strategic IT initiatives, including the SAP system upgrade that is progressing on track.
•As of March 31, 2026, cash, cash equivalents and short-term investments were $0.6 billion compared with $1.1 billion at year-end 2025. Key cash flow items during Q1 2026 included the $500 million synthetic share repurchase completed in January 2026, which reduced the outstanding shares by 10.9 million (or approximately 5%). The leverage ratio (net debt to adjusted EBITDA) increased to 1.3x at the end Q1 2026 from 0.7x at the end of 2025.
Portfolio update
QIAGEN is executing on targeted initiatives across its Sample to Insight portfolio to help customers around the world advance science and improve healthcare.
◦Sample technologies: QIAGEN advanced its automation roadmap with QIAsprint Connect showcased at the SLAS and AACR congresses in early 2026, alongside QIAsymphony Connect as an upgrade of the flagship QIAsymphony system and QIAmini for low-throughput automation. Parse Biosciences, which provides entry into the fast-growing single-cell analysis market segment, launched Evercode Whole Transcriptome v4, expanding scalability, sensitivity and workflow efficiency for single-cell RNA sequencing.
◦QIAstat-Dx: QIAGEN received U.S. regulatory clearance for Gastrointestinal Panels on the fully automated QIAstat-Dx Rise system, enabling labs to run both respiratory and gastrointestinal panels on one scalable platform. QIAGEN also expanded into bloodstream infection syndromic testing with the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, which identifies 20 pathogens and 10 antimicrobial resistance targets from positive blood cultures and colonies in about one hour. Development continues on new panels for complicated urinary tract infections, pneumonia and companion diagnostics.
◦QuantiFERON: QIAGEN highlighted new clinical and health economic data in Q1 2026 as part of World TB Day supporting QuantiFERON-TB Gold Plus in immunocompromised and other high-risk populations. Development is also advancing on AI-based TB risk prediction and further automation improvements through the Diasorin partnership that combines QuantiFERON with Diasorin's LIAISON systems for detection.
◦QIAGEN Digital Insights (QDI): QDI, the bioinformatics business of QIAGEN, introduced at the AACR meeting in April 2026 the QIAGEN Discovery Platform as an AI-grounding solution for drug discovery. The platform is designed to bring together biological knowledge, omics data and advanced analytics to support oncology research, with future implementation of AI functions and integration with downstream AI analysis.
4
Outlook
As announced on April 27, QIAGEN has updated its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). Key factors include headwinds from reduced QuantiFERON immigration testing demand, sustained caution among U.S. Life Sciences customers, the timing of customer orders in the OEM business and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least $2.43 CER (previously at least $2.50 CER). QIAGEN expects stronger growth trends in the second half of 2026, supported by the end of headwinds from the discontinuation of NeuMoDx and Dialunox, benefits from recent and planned product launches, sequential improvement in QuantiFERON sales, contributions from the Parse acquisition tracking ahead of the original target for 2026 and modestly improving trends in U.S. Life Sciences funding.
For Q2 2026, net sales are expected to decline approximately 2% CER from $534 million in Q2 2025. Adjusted diluted EPS is expected to be at least $0.60 CER compared to $0.60 in Q2 2025.
Based on exchange rates as of April 27, 2026, for full-year 2026, currency movements against the U.S. dollar are expected to have a positive impact on net sales of about one percentage point and a neutral impact on adjusted EPS results. For Q2 2026, currency movements against the U.S. dollar are expected to have a positive impact on net sales of about one percentage point and a neutral impact on adjusted EPS results.
QuantiFERON Spotlight Session on May 7, 2026
QIAGEN plans to hold a virtual Spotlight Session to provide insights into our strategic priorities for QuantiFERON and an update on the latest product enhancements. The online event, which is a new format that builds on the recent Deep Dives series, is scheduled for Thursday, May 7, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time. Registration details and further information about the webcast are available in the Investor Relations section of the QIAGEN website (www.qiagen.com), under Events and Presentations (https://corporate.qiagen.com/English/investor-relations/events-and-presentations/), with a recording accessible after the event.
Use of adjusted results
QIAGEN reports adjusted results and constant exchange rate (CER) measures, along with other non-GAAP financial metrics, to provide deeper insight into business performance. These include adjusted gross margin and profit, adjusted operating income and expenses, adjusted operating income margin, adjusted net income, adjusted income before taxes, adjusted diluted EPS, adjusted tax rate and free cash flow. Free cash flow is calculated as cash flow from operating activities less capital expenditures for property, plant and equipment. Adjusted results are non-GAAP measures that QIAGEN views as complementary to GAAP-reported results. They exclude items considered outside of ongoing core operations, subject to significant period-to-period fluctuation, or that reduce comparability with competitors and historical performance. QIAGEN also uses these non-GAAP and constant currency measures internally for planning, forecasting, reporting and employee compensation purposes. These metrics enable consistent comparison of current and past performance, which QIAGEN has historically presented on an adjusted basis.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and
5
industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Contacts
Investor Relations | Public Relations | |||||||||||||
e-mail: ir@QIAGEN.com | e-mail: pr@QIAGEN.com | |||||||||||||
6
QIAGEN N.V.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(In thousands, except per share data) | Three months | |||||||||||||
| ended March 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net sales | $492,320 | $483,456 | ||||||||||||
| Cost of sales: | ||||||||||||||
| Cost of sales | 169,459 | 161,294 | ||||||||||||
| Acquisition-related intangible amortization | 13,258 | 13,481 | ||||||||||||
| Total cost of sales | 182,717 | 174,775 | ||||||||||||
| Gross profit | 309,603 | 308,681 | ||||||||||||
| Operating expenses: | ||||||||||||||
| Sales and marketing | 114,606 | 106,334 | ||||||||||||
| Research and development | 48,261 | 43,783 | ||||||||||||
| General and administrative | 27,782 | 31,608 | ||||||||||||
| Acquisition-related intangible amortization | 2,328 | 1,793 | ||||||||||||
| Restructuring, acquisition, integration and other, net | 32,201 | 9,816 | ||||||||||||
| Total operating expenses | 225,178 | 193,334 | ||||||||||||
| Income from operations | 84,425 | 115,347 | ||||||||||||
| Other income (expense): | ||||||||||||||
| Interest income | 10,562 | 15,390 | ||||||||||||
| Interest expense | (11,051) | (7,294) | ||||||||||||
| Other income (expense), net | 1,893 | (3,894) | ||||||||||||
| Total other income, net | 1,404 | 4,202 | ||||||||||||
| Income before income tax expense | 85,829 | 119,549 | ||||||||||||
| Income tax expense | 17,786 | 28,791 | ||||||||||||
| Net income | $68,043 | $90,758 | ||||||||||||
Diluted earnings per common share | $0.33 | $0.41 | ||||||||||||
Diluted earnings per common share (adjusted) | $0.54 | $0.55 | ||||||||||||
| Diluted shares used in computing diluted earnings per common share | 208,939 | 220,189 | ||||||||||||
7
QIAGEN N.V.
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS
(In $ millions, except EPS data)
(unaudited)
Three months ended March 31, 2026 | Net Sales | Gross Profit | Operating Income | Pre-tax Income | Income Tax | Tax Rate | Net Income | Diluted EPS* | ||||||||||||||||||||||||||||||||||||||||||
| Reported results | 492.3 | 309.6 | 84.4 | 85.8 | (17.8) | 21 | % | 68.0 | $0.33 | |||||||||||||||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Business integration, acquisition and restructuring related items (a) | — | 2.5 | 34.7 | 34.7 | (9.9) | 24.8 | 0.12 | |||||||||||||||||||||||||||||||||||||||||||
| Purchased intangibles amortization (b) | — | 13.3 | 15.6 | 15.6 | (3.9) | 11.7 | 0.06 | |||||||||||||||||||||||||||||||||||||||||||
| Non-cash other income, net | — | — | — | 0.4 | (0.1) | 0.3 | 0.00 | |||||||||||||||||||||||||||||||||||||||||||
| Certain income tax items (c) | — | — | — | — | 7.7 | 7.7 | 0.04 | |||||||||||||||||||||||||||||||||||||||||||
| Total adjustments | — | 15.8 | 50.3 | 50.7 | (6.1) | 44.6 | 0.21 | |||||||||||||||||||||||||||||||||||||||||||
| Adjusted results | 492.3 | 325.4 | 134.7 | 136.5 | (23.9) | 18 | % | 112.6 | $0.54 | |||||||||||||||||||||||||||||||||||||||||
*Using 208.9 M diluted shares | ||||||||||||||||||||||||||||||||||||||||||||||||||
(a) Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects including subsequent integration activities at GNX Data Systems, Ltd. (Genoox) and Parse Biosciences (Parse).
(b) Adjustment includes the amortization of Genoox and Parse intangible assets acquired in Q2 2025 and Q4 2025, respectively.
(c) These items represent updates in QIAGEN's assessment of ongoing examinations or other tax items that are not indicative of the Company's normal future income tax expense.
Tables may contain rounding differences.
8
QIAGEN N.V.
CONDENSED CONSOLIDATED BALANCE SHEETS
| (In thousands, except par value) | March 31, 2026 | December 31, 2025 | ||||||||||||
| Assets | (unaudited) | |||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $646,289 | $839,005 | ||||||||||||
| Short-term investments | — | 259,913 | ||||||||||||
| Accounts receivable, net | 396,616 | 402,608 | ||||||||||||
| Inventories, net | 309,606 | 301,888 | ||||||||||||
| Prepaid expenses and other current assets | 187,743 | 191,659 | ||||||||||||
| Total current assets | 1,540,254 | 1,995,073 | ||||||||||||
| Long-term assets: | ||||||||||||||
| Property, plant and equipment, net | 914,789 | 923,948 | ||||||||||||
| Goodwill | 2,695,980 | 2,700,658 | ||||||||||||
| Intangible assets, net | 367,491 | 386,431 | ||||||||||||
| Other long-term assets | 263,551 | 275,122 | ||||||||||||
| Total long-term assets | 4,241,811 | 4,286,159 | ||||||||||||
| Total assets | $5,782,065 | $6,281,232 | ||||||||||||
Liabilities and equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accrued and other current liabilities | $400,812 | $439,481 | ||||||||||||
| Accounts payable | 78,298 | 72,656 | ||||||||||||
| Total current liabilities | 479,110 | 512,137 | ||||||||||||
| Long-term liabilities: | ||||||||||||||
| Long-term debt, net of current portion | 1,646,557 | 1,654,428 | ||||||||||||
| Other long-term liabilities | 324,692 | 336,513 | ||||||||||||
| Total long-term liabilities | 1,971,249 | 1,990,941 | ||||||||||||
| Equity: | ||||||||||||||
Common shares, 0.01 EUR par value, authorized—410,000 shares, issued—206,801 and 217,685 shares, respectively | 2,404 | 2,529 | ||||||||||||
| Additional paid-in capital | 949,272 | 1,436,360 | ||||||||||||
| Retained earnings | 2,802,017 | 2,748,390 | ||||||||||||
| Accumulated other comprehensive loss | (396,835) | (377,309) | ||||||||||||
Less treasury stock, at cost — 551 and 764 shares, respectively | (25,152) | (31,816) | ||||||||||||
| Total equity | 3,331,706 | 3,778,154 | ||||||||||||
| Total liabilities and equity | $5,782,065 | $6,281,232 | ||||||||||||
9
QIAGEN N.V.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
| (In thousands) | Three Months Ended March 31, | |||||||||||||
| 2026 | 2025 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||
| Net income | $68,043 | $90,758 | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||
| Depreciation and amortization | 51,211 | 43,908 | ||||||||||||
| Non-cash impairments | 15,218 | 2,537 | ||||||||||||
| Amortization of debt discount and issuance costs | 587 | 492 | ||||||||||||
| Share-based compensation expense | 9,651 | 12,339 | ||||||||||||
| Deferred tax benefit | (3,476) | (542) | ||||||||||||
| Loss on marketable securities | — | 968 | ||||||||||||
| Other items, net including fair value changes in derivatives | 1,532 | 3,883 | ||||||||||||
| Change in operating assets, net | (28,334) | 631 | ||||||||||||
| Change in operating liabilities, net | (13,803) | (15,234) | ||||||||||||
| Net cash provided by operating activities | 100,629 | 139,740 | ||||||||||||
| Cash flows from investing activities: | ||||||||||||||
| Purchases of property, plant and equipment | (46,883) | (43,902) | ||||||||||||
| Purchases of intangible assets | (1,598) | (362) | ||||||||||||
| Purchases of short-term investments | — | (25,000) | ||||||||||||
| Proceeds from redemptions of short-term investments | 259,294 | 189,679 | ||||||||||||
| Cash received for collateral asset | 1,040 | 926 | ||||||||||||
| Purchases of investments, net | (379) | (1,260) | ||||||||||||
| Net cash provided by investing activities | 211,474 | 120,081 | ||||||||||||
| Cash flows from financing activities: | ||||||||||||||
| Capital repayment | (496,749) | (280,086) | ||||||||||||
| Tax withholding related to vesting of stock awards | (7,752) | (4,942) | ||||||||||||
| Cash received (paid) for collateral liability | 1,128 | (1,480) | ||||||||||||
| Other financing activities | (286) | (196) | ||||||||||||
| Net cash used in financing activities | (503,659) | (286,704) | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | (1,160) | 2,084 | ||||||||||||
| Net decrease in cash and cash equivalents | (192,716) | (24,799) | ||||||||||||
| Cash and cash equivalents, beginning of period | 839,005 | 663,555 | ||||||||||||
| Cash and cash equivalents, end of period | $646,289 | $638,756 | ||||||||||||
Reconciliation of free cash flow:(1) | ||||||||||||||
| Net cash provided by operating activities | $100,629 | $139,740 | ||||||||||||
| Purchases of property, plant and equipment | (46,883) | (43,902) | ||||||||||||
| Free cash flow | $53,746 | $95,838 | ||||||||||||
(1) Free cash flow is a non-GAAP financial measure and is calculated from net cash provided by operating activities reduced by purchases of property, plant and equipment.
10
FAQ
How did QIAGEN (QGEN) perform financially in Q1 2026?
QIAGEN reported Q1 2026 net sales of $492.3 million, up 2% reported but down 1% at constant exchange rates. Net income was $68.0 million and diluted EPS was $0.33, both notably below the prior-year period’s $90.8 million and $0.41.
What were QIAGEN’s adjusted earnings and margins for Q1 2026?
QIAGEN posted adjusted diluted EPS of $0.54 in Q1 2026, slightly below $0.55 a year earlier. Adjusted operating income was $134.7 million, with an adjusted operating margin of 27.4%, down from 29.8%, reflecting integration costs, tariffs and currency impacts.
Why did QIAGEN lower its full-year 2026 outlook?
QIAGEN now expects 2026 net sales growth of about 1–2% at constant exchange rates and adjusted EPS of at least $2.43. This reduced outlook reflects weaker QuantiFERON immigration testing demand, cautious U.S. Life Sciences customer spending, OEM order timing and increased geopolitical uncertainty.
How did QuantiFERON and other key product groups perform for QIAGEN?
QuantiFERON Q1 2026 sales were $113 million, down 5% at constant exchange rates, mainly from lower immigration testing demand. Sample technologies grew 9% CER to $170 million, while Genomics/NGS rose 4% CER and PCR/Nucleic acid amplification declined 13% CER.
What happened to QIAGEN’s cash flow and leverage in Q1 2026?
QIAGEN generated $100.6 million in operating cash flow and $53.7 million in free cash flow in Q1 2026, both down versus 2025. A $500 million synthetic share repurchase reduced shares by about 5% and increased the leverage ratio to 1.3x from 0.7x.
What guidance did QIAGEN give for Q2 2026?
For Q2 2026, QIAGEN expects net sales to decline about 2% at constant exchange rates from $534 million in Q2 2025. Adjusted diluted EPS is forecast to be at least $0.60 at constant exchange rates, matching the prior-year’s adjusted diluted EPS level.